TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TYK Medicines, Inc. Class H ( (HK:2410) ) just unveiled an update.
TYK Medicines, Inc has announced proposed amendments to its Articles of Association, aiming to reform its organizational structure and enhance shareholder rights, including the abolishment of the Board of Supervisors. Additionally, the company plans to adopt a 2025 H Share Incentive Scheme to motivate and retain talent. These changes are subject to shareholder approval at an upcoming extraordinary general meeting, reflecting the company’s strategic move to align with the revised Company Law of China and improve corporate governance.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and providing medical solutions, with a market focus on enhancing shareholder value.
Average Trading Volume: 11,359,335
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.02B
Find detailed analytics on 2410 stock on TipRanks’ Stock Analysis page.